The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.

The latest price target for Vincerx Pharma (NASDAQ: VINC) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $5.00 expecting VINC to rise to within 12 months (a possible 376.19% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vincerx Pharma (NASDAQ: VINC) was provided by Cantor Fitzgerald, and Vincerx Pharma reiterated their overweight rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vincerx Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vincerx Pharma was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.

While ratings are subjective and will change, the latest Vincerx Pharma (VINC) rating was a reiterated with a price target of $0.00 to $5.00. The current price Vincerx Pharma (VINC) is trading at is $1.05, which is within the analyst’s predicted range.